The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

John Gommans, Qilong Yi, John W Eikelboom, Graeme J Hankey, Christopher Chen, Helen Rodgers, VITATOPS trial study group, John Gommans, Qilong Yi, John W Eikelboom, Graeme J Hankey, Christopher Chen, Helen Rodgers, VITATOPS trial study group

Abstract

Background: Homocysteine has been postulated as a novel, potentially reversible risk factor for osteoporosis and related fractures. We evaluated whether homocysteine-lowering therapy with B-vitamins in patients with symptomatic cerebrovascular disease reduced the incidence of osteoporotic fractures.

Methods: VITAmins To Prevent Stroke (VITATOPS) was a prospective randomised double-blind placebo-controlled trial in which 8,164 patients with recent (within 7 months) stroke or transient ischemic attack were randomly allocated to double-blind treatment with one tablet daily of either placebo (n = 4,075) or B-vitamins (folic acid 2 mg, vitamin B6 25 mg, vitamin B12 500 μg; n = 4,089). Patients were reviewed every six months. Any osteoporotic fracture and osteoporotic hip fractures were secondary outcome events, and were reviewed by a masked adjudication committee. Analysis was by intention to treat. Logistic regression was used to identify independent predictors of fracture.

Results: Participants had a mean age of 62.6 years (SD 12.5 years) and 64% were male, 42% of Western European descent and 75% were functionally independent (Oxford Handicap Scale of two or less). After a median duration of 2.8 years therapy and 3.4 years follow-up, there was no significant difference in the incidence of any osteoporotic fracture between participants assigned B-vitamins (67 [1.64%]) and placebo (78 [1.91%]; risk ratio [RR] 0.86, 95% confidence interval [CI] 0.62-1.18) or the incidence of hip fractures (34 [0.83%] B-vitamins vs. 36 [0.88%] placebo; RR 0.94, 95% CI 0.59-1.5). There was no significant impact of B-vitamin therapy on time to first fracture. Baseline homocysteine levels did not predict any osteoporotic fracture (p =0.43). Independent predictors of any osteoporotic fracture were female sex, age > 64 years, Western European ethnicity and use of anti-osteoporosis medication at randomization (all p < 0.01).

Conclusions: Once daily treatment with B-vitamins had no effect on incidence of osteoporotic fractures during a median of 3.4 years follow-up in patients with cerebrovascular disease. A modest effect of B-vitamin therapy is not excluded due to the low numbers of fracture outcome events.

Trial registration: ClinicalTrials.gov NCT00097669.

Figures

Figure 1
Figure 1
Kaplan Meier estimates of any osteoporotic fracture outcomes.
Figure 2
Figure 2
Kaplan Meier estimates of osteoporotic hip fracture outcomes.

References

    1. NIH Consensus Statement. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795. doi: 10.1001/jama.285.6.785.
    1. Herrmann M, Schmidt JP, Umanskaya N, Wagner A, Taban-Shomal O, Widmann T, Colaianni G, Wildemann B, Herrmann W. The role of hyperhomocysteinemia as well as folate, vitamin B(6) and B(12) deficiencies in osteoporosis: a systematic review. Clin Chem Lab Med. 2007;45:1621–1632.
    1. Melton LJ 3rd. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003;18:1139–1141. doi: 10.1359/jbmr.2003.18.6.1139.
    1. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int. 2005;16(Suppl 2):S8–S17.
    1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–475. doi: 10.1359/jbmr.061113.
    1. Raisz LG. Homocysteine and osteoporotic fractures–culprit or bystander? N Engl J Med. 2004;350:2089–2090. doi: 10.1056/NEJMe048030.
    1. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res. 2005;20:921–929. doi: 10.1359/JBMR.050202.
    1. Herrmann M, Widmann T, Herrmann W. Homocysteine - a newly recognised risk factor for osteoporosis. Clin Chem Lab Med. 2005;43:1111–1117.
    1. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, Pluijm SMF, van der Klift M, de Jonge R, Lindemans J, de Groot LCPGM, Hofman A, Witterman JCM, van Leeuwen JPTM, Breteler MMB, Lips P, Pols HAP, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033–2041. doi: 10.1056/NEJMoa032546.
    1. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350:2042–2049. doi: 10.1056/NEJMoa032739.
    1. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Meyer HE, Tell GS. Plasma homocysteine, folate, and vitamin B 12 and the risk of hip fracture: the hordaland homocysteine study. J Bone Miner Res. 2007;22:747–756. doi: 10.1359/jbmr.070210.
    1. Levasseur R. Bone tissue and hyperhomocysteinemia. Joint Bone Spine. 2009;76:234–240. doi: 10.1016/j.jbspin.2008.11.002.
    1. McLean RR, Jacques PF, Selhub J, Fredman L, Tucker KL, Samelson EJ, Kiel DP, Cupples LA, Hannan MT. Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrinol Metab. 2008;93:2206–2212. doi: 10.1210/jc.2007-2710.
    1. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Vaananen HK, Obrant KJ, Akesson K. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007;22:127–134.
    1. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003;41:1392–1403.
    1. Homocysteine Trialists Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82:806–812.
    1. Green TJ, McMahon JA, Skeaff CM, Williams SM, Whiting SJ. Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial. Am J Clin Nutr. 2007;85:460–464.
    1. Herrmann M, Stanger O, Paulweber B, Hufnagl C, Herrmann W. Folate supplementation does not affect biochemical markers of bone turnover. Clin Lab. 2006;52:131–136.
    1. Herrmann M, Umanskaya N, Traber L, Schmidt-Gayk H, Menke W, Lanzer G, Lenhart M, Schmidt JP, Herrmann W. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial. Clin Chem Lab Med. 2007;45:1785–1792.
    1. Keser I, Ilich JZ, Vrkic N, Giljevic Z, Colic Baric I. Folic acid and vitamin B12 supplementation lowers plasma homocysteine but has no effect on serum bone turnover markers in elderly women: a randomized, double-blind, placebo-controlled trial. Nutr Res. 2013;33:211–219. doi: 10.1016/j.nutres.2013.01.002.
    1. Sawka AM, Ray JG, Yi Q, Josse RG, Lonn E. Randomized clinical trial of homocysteine level lowering therapy and fractures. Arch Intern Med. 2007;167:2136–2139. doi: 10.1001/archinte.167.19.2136.
    1. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577.
    1. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA. 2005;293:1082–1088. doi: 10.1001/jama.293.9.1082.
    1. van Meurs JB, Uitterlinden AG. Homocysteine and fracture prevention. JAMA. 2005;293:1121–1122. doi: 10.1001/jama.293.9.1121.
    1. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120–126.
    1. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010;9:855–865.
    1. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229. doi: 10.1136/bmj.b4229.
    1. Moayyeri A, Alrawi YA, Myint PK. The complex mutual connection between stroke and bone health. Arch Biochem Biophys. 2010;503:153–159. doi: 10.1016/j.abb.2010.06.023.
    1. Sandercock P. Vitamin B supplements for prevention of stroke. Lancet Neurol. 2010;9:842–843. doi: 10.1016/S1474-4422(10)70188-5.
    1. van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, van der Velde N, Swart KM, Enneman AW, van Dijk SC, Bouwer-Brolsma EM, Zillikens MC, van Meurs JB, Brug J, Uitterlinden AG, Lips P, de Groot LC. Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence. BMC Geriatr. 2011;11:80. doi: 10.1186/1471-2318-11-80.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner